Validity of the animal models for nephrogenic systemic fibrosis [1]

Investigative Radiology

Volumn 43, Issue 5, 2008, Pages 338-

  Morcos, Sameh K ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; CONTRAST MEDIUM;

AREA UNDER THE CURVE; DISEASE SEVERITY; EXPERIMENTAL MODEL; FIBROSIS; LETTER; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; KIDNEY FAILURE; MALE; METABOLIC CLEARANCE RATE; METABOLISM; NOTE; RAT; REPRODUCIBILITY; SKIN DISEASE; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; GADOLINIUM DTPA; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; SKIN DISEASES;

EID: 42449140319     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31816c4298     Document Type: Letter

References (3)

1. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
2. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73-76.
3. Ahmed AK, Haylor JL, El Nahas AM, et al. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int. 2007;71:755-763.